References
- IvySPSiuLLGarrett-MayerERubinsteinLApproaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committeeClin Cancer Res20101661726173620215542
- US Food Drug AdministrationGuidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy VolunteersRockville, MDFood and Drug Administration2005 Available from: http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdfAccessed July 6, 2005
- Committee for Medicinal Products for Human UseGuideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medical ProductsLondon, UKEuropean Medicines Agency2007 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdfAccessed July 19, 2007
- ReichertJMRosensweigCJFadenLBDewitzMCMonoclonal antibody successes in the clinicNat Biotech200523910731078
- StebbingsRPooleSThorpeRSafety of biologics, lessons learnt from TGN1412Curr Opin Biotechnol200920667367719892543
- SuntharalingamGPerryMRWardSCytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412N Engl J Med2006355101018102816908486
- TibbittsJCavagnaroJAHallerCAMarafinoBAndrewsPASullivanJTPractical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticalsRegul Toxicol Pharmacol201058224325120558225
- SharmaVMcNeillJHTo scale or not to scale: the principles of dose extrapolationB J Pharmacol20091576907921
- Le TourneauCStathisAVidalLMooreMJSiuLLChoice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trialsJ Clin Oncol20102881401140720124167
- ZouPYuYZhengNApplications of human pharmacokinetic prediction in first-in-human dose estimationAAPS J201214226228122407287
- AgoramBMUse of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologicsBr J Clin Pharmacol200967215316019076987
- HansenARCookNRicciMSChoice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trialsOncologist201520665365925964306
- TosiDLaghzaliYVinchesMClinical development strategies and outcomes in first-in-human trials of monoclonal antibodiesJ Clin Oncol201533192158216526014300
- RosenLSHurwitzHIWongMKA phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancerClin Cancer Res201218174820482922767667
- AgoramBMMartinSWvan der GraafPHThe role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologicsDrug Discov Today200712231018102418061880
- WangWWangEBalthasarJMonoclonal antibody pharmacokinetics and pharmacodynamicsClin Pharmacol Ther200884554855818784655
- MiltonMNHorvathCJThe EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical developmentToxicol Pathol200937336337119246571
- LowePJHijaziYLuttringerOYinHSarangapaniRHowardDOn the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug developmentXenobiotica20073710–111331135417968748
- BokkersBGSlobWDeriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approachCrit Rev Toxicol200737535537317612951
- ZhaoLRenT-hWangDDClinical pharmacology considerations in biologics developmentActa Pharmacol Sin201233111339134723001474
- MullerPYMiltonMLloydPSimsJBrennanFRThe minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodiesCurr Opin Biotechnol200920672272919896825
- EasterbrookPJGopalanRBerlinJMatthewsDRPublication bias in clinical researchLancet199133787468678721672966